Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Research & Development for 10 consecutive years, with $40.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 118.09% year-over-year to $40.9 million; the trailing twelve-month figure through Jun 2026 stood at $127.1 million (up 27.98% YoY), and the FY2025 full-year result was $96.9 million, down 13.23% from the prior year.
• Research & Development grew to $40.9 million in Q2 2026 per KNSA's latest filing, from $27.5 million in the prior quarter.
• Across five years, Research & Development topped out at $40.9 million in Q2 2026 and bottomed at $13.8 million in Q2 2022.
• Historically, Research & Development has averaged $23.2 million across 5 years, with a median of $22.3 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Research & Development slumped 47.54% in 2022, then jumped 118.09% in 2026.
• Over 5 years, Research & Development stood at $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then jumped by 75.62% to $35.2 million in 2024, then decreased by 1.72% to $34.6 million in 2025, then rose by 18.17% to $40.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $40.9 million, $27.5 million, and $34.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.